title: Different effects of typical and atypical antipsychotics on grey matter in first episode psychosis: the AESOP study.
abstract: Typical antipsychotic drugs act on the dopaminergic system, blocking the dopamine type 2 (D2) receptors. Atypical antipsychotics have lower affinity and occupancy for the dopaminergic receptors, and a high degree of occupancy of the serotoninergic receptors 5-HT2A. Whether these different pharmacological actions produce different effects on brain structure remains unclear. We explored the effects of different types of antipsychotic treatment on brain structure in an epidemiologically based, nonrandomized sample of patients at the first psychotic episode. Subjects were recruited as part of a large epidemiological study (AESOP: aetiology and ethnicity in schizophrenia and other psychoses). We evaluated 22 drug-free patients, 32 on treatment with typical antipsychotics and 30 with atypical antipsychotics. We used high-resolution MRI and voxel-based methods of image analysis. The MRI analysis suggested that both typical and atypical antipsychotics are associated with brain changes. However, typicals seem to affect more extensively the basal ganglia (enlargement of the putamen) and cortical areas (reductions of lobulus paracentralis, anterior cingulate gyrus, superior and medial frontal gyri, superior and middle temporal gyri, insula, and precuneus), while atypical antipsychotics seem particularly associated with enlargement of the thalami. These changes are likely to reflect the effect of antipsychotics on the brain, as there were no differences in duration of illness, total symptoms scores, and length of treatment among the groups. In conclusion, we would like to suggest that even after short-term treatment, typical and atypical antipsychotics may affect brain structure differently.
authors.affiliation: Division of Psychological Medicine, Institute of Psychiatry, King's College, London, UK. spcbpad@iop.kcl.ac.uk
authors.forename: Paola
authors.initials: P
authors.lastname: Dazzan
authors.forename: Kevin D
authors.initials: KD
authors.lastname: Morgan
authors.forename: Ken
authors.initials: K
authors.lastname: Orr
authors.forename: Gerard
authors.initials: G
authors.lastname: Hutchinson
authors.forename: Xavier
authors.initials: X
authors.lastname: Chitnis
authors.forename: John
authors.initials: J
authors.lastname: Suckling
authors.forename: Paul
authors.initials: P
authors.lastname: Fearon
authors.forename: Philip K
authors.initials: PK
authors.lastname: McGuire
authors.forename: Rosemarie M
authors.initials: RM
authors.lastname: Mallett
authors.forename: Peter B
authors.initials: PB
authors.lastname: Jones
authors.forename: Julian
authors.initials: J
authors.lastname: Leff
authors.forename: Robin M
authors.initials: RM
authors.lastname: Murray
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D014150:Antipsychotic Agents / Q000145:classification / Q000494:pharmacology* / Q000627:therapeutic use; D001479:Basal Ganglia / Q000187:drug effects / Q000473:pathology; D001921:Brain / Q000187:drug effects* / Q000473:pathology* / Q000503:physiopathology; D002540:Cerebral Cortex / Q000187:drug effects / Q000473:pathology; D005260:Female; D006801:Humans; D007091:Image Processing, Computer-Assisted; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D018579:Patient Selection; D011618:Psychotic Disorders / Q000188:drug therapy* / Q000473:pathology* / Q000503:physiopathology; D012559:Schizophrenia / Q000188:drug therapy / Q000473:pathology / Q000503:physiopathology; D013788:Thalamus / Q000187:drug effects / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D014150:Antipsychotic Agents